Voya Investment Management LLC Has $678,000 Stock Position in Bicycle Therapeutics plc (NASDAQ:BCYC)

Voya Investment Management LLC lowered its position in Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 54.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 48,420 shares of the company's stock after selling 56,870 shares during the period. Voya Investment Management LLC owned 0.07% of Bicycle Therapeutics worth $678,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Candriam S.C.A. grew its holdings in Bicycle Therapeutics by 3.5% during the 4th quarter. Candriam S.C.A. now owns 1,087,876 shares of the company's stock worth $15,230,000 after acquiring an additional 37,278 shares during the period. Long Focus Capital Management LLC acquired a new position in shares of Bicycle Therapeutics in the 4th quarter valued at $7,603,000. Principal Financial Group Inc. acquired a new position in shares of Bicycle Therapeutics in the 3rd quarter valued at $10,028,000. Platinum Investment Management Ltd. boosted its stake in Bicycle Therapeutics by 13.6% in the 4th quarter. Platinum Investment Management Ltd. now owns 309,059 shares of the company's stock worth $4,327,000 after purchasing an additional 36,910 shares during the period. Finally, Springhill Fund Asset Management HK Co Ltd acquired a new position in Bicycle Therapeutics in the 4th quarter worth $1,630,000. Institutional investors own 86.15% of the company's stock.

Bicycle Therapeutics Trading Down 0.1%

NASDAQ:BCYC traded down $0.01 on Wednesday, hitting $8.10. The company had a trading volume of 76,146 shares, compared to its average volume of 401,197. The stock has a market capitalization of $560.96 million, a price-to-earnings ratio of -2.46 and a beta of 1.60. The firm has a 50 day moving average of $8.36 and a two-hundred day moving average of $13.53. Bicycle Therapeutics plc has a 52 week low of $6.10 and a 52 week high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.02). The business had revenue of $9.98 million for the quarter, compared to the consensus estimate of $8.67 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. As a group, equities analysts forecast that Bicycle Therapeutics plc will post -3.06 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Royal Bank of Canada cut their price target on shares of Bicycle Therapeutics from $35.00 to $32.00 and set an "outperform" rating on the stock in a research report on Friday, May 2nd. Needham & Company LLC reaffirmed a "buy" rating and issued a $29.00 target price on shares of Bicycle Therapeutics in a report on Friday, May 2nd. HC Wainwright reaffirmed a "buy" rating and issued a $33.00 target price on shares of Bicycle Therapeutics in a report on Wednesday, February 26th. B. Riley dropped their target price on shares of Bicycle Therapeutics from $17.00 to $14.00 and set a "neutral" rating on the stock in a report on Friday, May 2nd. Finally, JMP Securities lowered their price target on shares of Bicycle Therapeutics from $26.00 to $22.00 and set a "market outperform" rating on the stock in a report on Friday, May 2nd. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $25.00.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.